Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report

Slatina Christov, Frenz Ohm, Matthias Augustin, Jan Nicolai Wagner Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, GermanyCorrespondence: Jan Nicolai Wagner, Institute for Health Services Research in Dermatol...

Full description

Saved in:
Bibliographic Details
Main Authors: Christov S, Ohm F, Augustin M, Wagner JN
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Psoriasis: Targets and Therapy
Subjects:
Online Access:https://www.dovepress.com/successful-treatment-of-linear-psoriasis-with-the-il-17a-antagonist-ix-peer-reviewed-fulltext-article-PTT
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832592056606785536
author Christov S
Ohm F
Augustin M
Wagner JN
author_facet Christov S
Ohm F
Augustin M
Wagner JN
author_sort Christov S
collection DOAJ
description Slatina Christov, Frenz Ohm, Matthias Augustin, Jan Nicolai Wagner Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, GermanyCorrespondence: Jan Nicolai Wagner, Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany, Tel +49 (0) 40 74 10 52398, Fax +49 (0) 40 7410 55348, Email ja.wagner@uke.deAbstract: Linear psoriasis (LP) represents a rare variant of psoriasis. The clinical presentation includes erythematous plaques distributed along the Blaschko lines, reflecting the presence of embryological mosaicism. The clinical and histopathological features of this condition show many similarities with inflammatory linear verrucous epidermal nevus (ILVEN), which presents a challenge in differential diagnosis. Currently there is no disease-specific treatment guidelines causing a challenge in the therapeutic management. In this case report we describe a 28-year-old patient with LP. Clinically characterized by persistent, psoriasiform lesions that proved refractory to treatment with topical corticosteroids, vitamin D analogs, and systemic dimethyl fumarate. The histopathological findings showed psoriasiform epidermal hyperplasia with alternating ortho- and parakeratosis, subepidermal capillary dilatation, and perivascular lymphocytic infiltrates, confirming the diagnosis. Ixekizumab, a IL-17A antagonist, was administered leading to a rapid and significant reduction in disease severity within the first 16 weeks. The Psoriasis Area and Severity Index (PASI) decreased from 12.5 to 1.0 and as well as the Dermatology Life Quality Index (DLQI) improved to 1. Both scores prove significant improvement in quality of life and clinical severity. This case report shows the importance of histological confirmation in differentiating LP from clinically similar appearing diseases like ILVEN and highlights the potential therapeutic benefit of IL-17 blockade in LP. In addition, the findings emphasize the need for systematic studies to develop evidence-based treatment strategies for this rare psoriasis phenotype.Keywords: psoriasis, linear psoriasis, biologics, genodermatosis, ILVEN, IL-17A-antagonist, ixekizumab
format Article
id doaj-art-33997141888c47c7849445500beae172
institution Kabale University
issn 2230-326X
language English
publishDate 2025-01-01
publisher Dove Medical Press
record_format Article
series Psoriasis: Targets and Therapy
spelling doaj-art-33997141888c47c7849445500beae1722025-01-21T16:58:07ZengDove Medical PressPsoriasis: Targets and Therapy2230-326X2025-01-01Volume 15232899446Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case ReportChristov SOhm FAugustin MWagner JNSlatina Christov, Frenz Ohm, Matthias Augustin, Jan Nicolai Wagner Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, GermanyCorrespondence: Jan Nicolai Wagner, Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany, Tel +49 (0) 40 74 10 52398, Fax +49 (0) 40 7410 55348, Email ja.wagner@uke.deAbstract: Linear psoriasis (LP) represents a rare variant of psoriasis. The clinical presentation includes erythematous plaques distributed along the Blaschko lines, reflecting the presence of embryological mosaicism. The clinical and histopathological features of this condition show many similarities with inflammatory linear verrucous epidermal nevus (ILVEN), which presents a challenge in differential diagnosis. Currently there is no disease-specific treatment guidelines causing a challenge in the therapeutic management. In this case report we describe a 28-year-old patient with LP. Clinically characterized by persistent, psoriasiform lesions that proved refractory to treatment with topical corticosteroids, vitamin D analogs, and systemic dimethyl fumarate. The histopathological findings showed psoriasiform epidermal hyperplasia with alternating ortho- and parakeratosis, subepidermal capillary dilatation, and perivascular lymphocytic infiltrates, confirming the diagnosis. Ixekizumab, a IL-17A antagonist, was administered leading to a rapid and significant reduction in disease severity within the first 16 weeks. The Psoriasis Area and Severity Index (PASI) decreased from 12.5 to 1.0 and as well as the Dermatology Life Quality Index (DLQI) improved to 1. Both scores prove significant improvement in quality of life and clinical severity. This case report shows the importance of histological confirmation in differentiating LP from clinically similar appearing diseases like ILVEN and highlights the potential therapeutic benefit of IL-17 blockade in LP. In addition, the findings emphasize the need for systematic studies to develop evidence-based treatment strategies for this rare psoriasis phenotype.Keywords: psoriasis, linear psoriasis, biologics, genodermatosis, ILVEN, IL-17A-antagonist, ixekizumabhttps://www.dovepress.com/successful-treatment-of-linear-psoriasis-with-the-il-17a-antagonist-ix-peer-reviewed-fulltext-article-PTTpsoriasislinear psoriasisbiologicsgenodermatosisilvenil-17a-antagonistixekizumab.
spellingShingle Christov S
Ohm F
Augustin M
Wagner JN
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
Psoriasis: Targets and Therapy
psoriasis
linear psoriasis
biologics
genodermatosis
ilven
il-17a-antagonist
ixekizumab.
title Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
title_full Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
title_fullStr Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
title_full_unstemmed Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
title_short Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
title_sort successful treatment of linear psoriasis with the il 17a antagonist ixekizumab a case report
topic psoriasis
linear psoriasis
biologics
genodermatosis
ilven
il-17a-antagonist
ixekizumab.
url https://www.dovepress.com/successful-treatment-of-linear-psoriasis-with-the-il-17a-antagonist-ix-peer-reviewed-fulltext-article-PTT
work_keys_str_mv AT christovs successfultreatmentoflinearpsoriasiswiththeil17aantagonistixekizumabacasereport
AT ohmf successfultreatmentoflinearpsoriasiswiththeil17aantagonistixekizumabacasereport
AT augustinm successfultreatmentoflinearpsoriasiswiththeil17aantagonistixekizumabacasereport
AT wagnerjn successfultreatmentoflinearpsoriasiswiththeil17aantagonistixekizumabacasereport